Mochi Health Peptides: GLP-1 Compounds in the Program

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This PlexusDx Education Hub overview explains what "peptides" means inside a GLP-1 program and how a telehealth service works with them. Browse all Peptides & GLP-1 education

Independent editorial note: PlexusDx operates a competing weight-management program and holds no affiliate link, partnership, or commercial relationship with Mochi Health.

When a weight-management program is described in terms of "peptides," the word points to the GLP-1 compounds at its core. This editorial clarifies which peptide compounds a program like Mochi Health works with, how compounded and brand-name versions differ, what the peptide research supports, and how your own genome maps onto these pathways. Fair-balance framing, current as of April 2026.

What "peptides" means in a GLP-1 program

GLP-1 medications are peptide compounds — short chains of amino acids that act as incretin signals. In everyday program language, "peptides" is shorthand for this class: GLP-1 receptor agonists and GIP/GLP-1 dual agonists used for metabolic and weight-management purposes. Understanding that framing keeps the conversation grounded in specific, well-characterized compounds rather than a vague category.

The peptide compounds Mochi Health works with

Mochi Health (Mochi Health) operates as telehealth with insurance support, and the peptide compounds relevant to programs in this model are semaglutide and tirzepatide. A licensed clinician reviews an intake and, when eligibility is met, routes a prescription to either a retail pharmacy for an FDA-approved brand product or a 503A compounding pharmacy for a compounded formulation. The program's specifics are documented at Mochi Health's official website.

Compounded versus brand-name peptide therapy

The same peptide can reach you two ways. Brand-name products are FDA-approved and dispensed by retail pharmacies; compounded semaglutide or tirzepatide is prepared by a 503A compounding pharmacy against an individual prescription. Both routes deliver the same active peptide but differ in regulatory status, availability, and cost. Which one a program uses determines exactly what you receive, so it is worth confirming the pharmacy pathway rather than assuming every program handles these peptides the same way.

What peptide research supports

The peptide compounds in this space are among the most studied in metabolic medicine. GLP-1 receptor agonists include semaglutide, liraglutide, and dulaglutide; tirzepatide is a GIP/GLP-1 dual agonist. Pivotal programs include STEP (semaglutide, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Populations and endpoints differ across these programs, and individual outcomes vary from one person to the next.

Mapping the peptide pathways in your own genome

Every peptide in this class acts through pathways your genes help define. Variants in GLP1R (the GLP-1 receptor these peptides target), FTO (the fat-mass and obesity-associated gene), MC4R (central to satiety), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) map your baseline metabolic terrain. They are pathway-level markers — they do not predict response to any specific peptide, but they describe the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Tirzepatide Injection, and oral formats. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including the variants above. For more, see GLP 1 Hormone and GLP 1 Receptor Agonist.

Not affiliated: PlexusDx has no commercial relationship with Mochi Health.

Disclaimer: This overview is educational. PlexusDx is not affiliated with Mochi Health. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, so this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the peptide options with genetic context: view the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions About Mochi Health Peptides

Which peptides does a GLP-1 program like Mochi Health use?

The relevant peptide compounds are semaglutide, a GLP-1 receptor agonist, and tirzepatide, a GIP/GLP-1 dual agonist. Both are well-studied incretin peptides used for metabolic and weight-management purposes, dispensed either as FDA-approved brand products or as compounded formulations depending on the program and pharmacy pathway.

Are compounded peptides different from brand-name peptides?

The active peptide is the same. Brand-name products are FDA-approved and filled by retail pharmacies, while compounded semaglutide or tirzepatide is prepared by a 503A compounding pharmacy against an individual prescription. The differences are regulatory status, availability, and cost, not the underlying molecule you receive.

Is peptide therapy well supported by research?

The core GLP-1 peptides are extensively studied. STEP (NEJM 2021) examined semaglutide, while SURMOUNT (NEJM 2022) and SURMOUNT-OSA (NEJM 2024) examined tirzepatide. Trial populations and endpoints vary, and individual outcomes differ, so the evidence describes the compound class rather than any one person's result.

Can a genetic test match me to the right peptide?

No. The Precision Peptide Genetic Test does not predict response or match you to a compound. It maps pathway-level variants such as FTO across 14 pathways and 49 peptides, giving you and your provider baseline biological context rather than a recommendation for any specific peptide.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.